Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Wino115on Dec 23, 2021 2:30pm
191 Views
Post# 34258827

RE:RE:RE:Trestle

RE:RE:RE:Trestle I believe this is not a finanial function, but the regulatory and compliance interface for US drug/healthcare regulations and legal issues.  Sales, manufacturing, development --the whole thing. I don't think it's someone to help on finding partners or M&A per se.

jfm1330 wrote: From his Linkedin page



Support the Senior Executive Team, Commercial and Medical Teams to design, implement and operationalize a well-designed, properly scaled U.S. Compliance Program that meets U.S. OIG and DOJ guidances and leading industry practices to support commercial U.S. operations.










SPCEO1 wrote: How did you find out that THTX had contracted with this company?

scarlet1967 wrote:

 

Last month THTX contracted Steve Vincze 

the founder of Trestle based in Boston. This company offers various services among others the below.

 

https://www.linkedin.com/in/stevevincze

 

“We understand the rigors, timing, speed and valuation implications of an effective compliance program due diligence review, whether for a buyer or a seller or for a public or private transaction.


Merger & Acquisition Transactions

Due Diligence 

Joint Ventures & Strategic Alliances…”


 




<< Previous
Bullboard Posts
Next >>